Cipla unit's US facility receives 5 observations from American drug regulator; shares fall
Cipla shares remained under pressure on Thursday after the US drug regulator issued five observations about a New York-based facility of the company's wholly-owned subsidiary, InvaGen Pharmaceuticals.
Cipla shares remained under pressure on Thursday, after the US drug regulator issued five observations about a New York-based facility of the company's wholly-owned subsidiary, InvaGen Pharmaceuticals. The Cipla stock declined by as much as Rs 35, or 2.8 per cent, to Rs 1,203.9 apiece on BSE in an overall weak Mumbai market, before settling at Rs 1,209.9 apiece for the day.
In a regulatory filing post-market hours on Wednesday, Cipla said the US Food and Drug Administration (USFDA) conducted a "routine current good manufacturing practices (cGMP)" inspection at InvaGen Pharmaceuticals' manufacturing facility located in Central Islip in Long Island, New York, from September 11 to September 19. The regulator also conducted a pre-approval inspection for a site transfer product within InvaGen.
After the completion of the inspection, InvaGen received five observations in Form 483 from the FDA. "There are no repeat or data integrity (DI) observations. The Company will work closely with the USFDA and is committed to addressing these comprehensively within stipulated time," the filing added.
Form 483, also known as the notice of inspectional observations, is issued at the end of an inspection by the US health regulator in cases where the field authorities come across deficiencies in quality systems, or find conditions violating food and drug safety laws.
(This story will be updated shortly)
Catch latest stock market updates here. For all other news related to business, politics, tech, sports and auto, visit Zeebiz.com.
Get Latest Business News, Stock Market Updates and Videos; Check your tax outgo through Income Tax Calculator and save money through our Personal Finance coverage. Check Business Breaking News Live on Zee Business Twitter and Facebook. Subscribe on YouTube.
RECOMMENDED STORIES
If you make RDs of Rs 5,000, Rs 10,000, Rs 15,000, and Rs 20,000 in post office, what will be your maturity amount?
Special Live Trading Session on Saturday: Know why BSE, NSE will remain open on May 18; check timings
RCB vs CSK IPL 2024 Ticket Booking Online: Where and how to buy RCB vs CSK tickets online - Check IPL Match 68 ticket price, other details
Women loco pilots speak about their struggle; many men have to be informed even for 'washroom break' in a moving train
Bandhan Bank Q4 FY24 Results Preview: PAT, interest income likely to grow in almost double digits; asset quality may improve
04:28 PM IST